Glyxambi Contraindications


Boehringer Ingelheim


The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Hypersensitivity to the active substances, to any other Sodium-Glucose-Co-Transporter-2 (SGLT2) inhibitor, to any other Dipeptidyl-Peptidase-4 (DPP-4) inhibitor, or to any of the excipients listed in Description.
Patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR < 30 ml/min/1.73m2 or ClCr < 30 ml/min) or eGFR persistently < 45 ml/min/1.73m2 or ClCr persistently < 45 ml/min (CKD Stage 3B). The efficacy of empagliflozin is dependent on renal function (see Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in